Bill Sellers, Delphia Therapeutics co-founder (Broad Institute)

For decades, can­cer drug de­vel­op­ers have fo­cused on in­hi­bi­tion. Now, a GV-backed start­up is eye­ing ac­ti­va­tion

One of the back­bones of can­cer med­i­cine is shut­ting down key can­cer-dri­ving path­ways to kill tu­mor cells. But for years, re­searchers have no­ticed hy­per­ac­ti­va­tion of cer­tain sig­nals in these path­ways can lead to the same re­sult.

Re­searchers from Bill Sell­ers’ lab at the Broad In­sti­tute want­ed to fig­ure out how wide­ly hy­per­ac­ti­va­tion could be ap­plied to kill tu­mor cells. They ex­plored over-ac­ti­vat­ing three ma­jor can­cer-dri­ving path­ways across near­ly 500 cell lines, and they found that over-ac­ti­vat­ing cer­tain sig­nals in all three path­ways could keep tu­mor cells at bay, ac­cord­ing to a new study in Na­ture Ge­net­ics pub­lished Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.